TGFB1 and breast cancer: Furthermore, the knockdown of Malat1 inhibited TGF-β-induced EMT and its targeted inhibition suppressed the migration and invasion characteristics triggered by TGF-β [84], suggesting that targeting TGF-β through Malat1 could be a promising therapeutic option for stopping BC progression.